News / USA

US Launches Campaign Against Alzheimer's, Including Prevention Drug Trials

US Health and Human Services Secretary Kathleen Sebelius (file photo)US Health and Human Services Secretary Kathleen Sebelius (file photo)
x
US Health and Human Services Secretary Kathleen Sebelius (file photo)
US Health and Human Services Secretary Kathleen Sebelius (file photo)
Jessica Berman
The U.S. government has announced a major education and research campaign to fight Alzheimer's disease.  As part of that effort, scientists are stepping up their efforts to develop drugs by the middle of the next decade that could prevent the incurable brain-wasting disease.  

Two Alzheimer's disease prevention trials are receiving money from the National Institutes of Health, or NIH, as part of the Obama administration's new national strategy to fight the growing problem of Alzheimer's in the U.S. and around the world.  

An estimated 5.4 million Americans suffer from Alzheimer's or some form of dementia.  The number is expected to grow exponentially as the U.S. population ages, and reach 7.7 million by 2030.  By then, Alzheimer's and other dementia disorders could be affecting as many as 66 million people worldwide.

The so-called National Alzheimer's Plan calls on scientists to develop treatments to prevent the disease by 2025. NIH has set aside $50 million to help fund the effort.  NIH director Francis Collins says the studies herald a new era in Alzheimer's disease research.

"We have learned more about this disease in the last couple of years than probably ever before," said Collins. "And now the goal is to take that and translate it into interventions."

Collins was speaking at an NIH-sponsored conference of the nation's top Alzheimer's researchers.

Scientists at the Banner Alzheimer's Institute in Arizona announced they will be conducting human trials early next year of an experimental drug, called crenezumab, that they hope will prevent the disease.

The study will involve members of a large extended family living in remote villages within several hundred kilometers of each other near Medellin, Colombia.  Some of the thousands of relatives carry an extremely a rare genetic mutation that inevitably causes early on-set Alzheimer's.  

Those with the genetic flaw begin showing cognitive declines in their mid-forties and are destined to develop full-blown Alzheimer's by their early 50's.

The Banner Institute's Pierre Tariot is one of the lead investigators. Addressing the ethical questions some critics have raised about testing drugs on healthy people in a poor developing country, Tariot says all of the study participants have been fully informed about the possibility that the drug might not work, or that they might get a placebo that does not contain crenezumab.  

Tariot says they still wanted to participate.

"They have been faced with this devastating illness hitting every generation for hundreds of years," said Tariot. "As one of them put it, 'There are many rivers to cross but at least we are at the first bank.'  And that's kind of the attitude that people have had."

Three hundred individuals have signed up for the trial; one-third will receive crenezumab and the others will be given a placebo. The trial will also include a smaller number of individuals in the United States.

If the therapy works in those with early-onset disease, scientists hope it may also help older individuals.

Cremezumab is a vaccine that targets the brain plaques or amyloid protein deposits that are thought to underlie development of Alzheimer's, according to Banner's Eric Reiman, who will help lead the study.

"Crenezumab is an antibody treatment that is intended to bind with amyloid and remove it from the brain," said Reiman.

Injections of crenezumab or placebo will be administered every two weeks.  

The $100-million Colombia trial is slated to last five years, but researchers predict they could see results within two.  NIH is providing $16 million to support the research; Banner is contributing another $15 million.  The major share of the funding - about $65 million - will come from the drug's American manufacturer, Genentech.

A second Alzheimer's drug trial, also funded by NIH, has shown that a nasal insulin spray used twice daily by people with mild cognitive dysfunction seemed to improve their symptoms, offering hope that Alzheimer's could be treated or even prevented.

You May Like

US Firms Concerned About China's New Cyber Regulations

New rules would require technology companies doing business in financial sector to hand over their source code, adopt Chinese encryption algorithms More

WHO Focus on Ebola Shifts to Ending Outbreak

Focus to be less on building facilities and more on efforts to find infected people, manage their cases, engage with communities and ensure proper burials More

US Scientist Who Conceived of Groundbreaking Laser Technology Dies

Charles Townes, Nobel laureate, laser co-creator paved way for other scientific discoveries: CDs, eye surgery, metal cutters to name a few technologies that rely on lasers More

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Super Bowl Ads Compete for Eyes on TV, Webi
X
January 29, 2015 9:58 AM
Super Bowl Sunday (Feb. 1) is about more than just the NFL's American football championship and big parties to watch the game. Viewers also tune in for the world famous commercials that send Facebook and Twitter abuzz. Daniela Schrier reports on the social media rewards for America’s priciest advertising.
Video

Video Super Bowl Ads Compete for Eyes on TV, Web

Super Bowl Sunday (Feb. 1) is about more than just the NFL's American football championship and big parties to watch the game. Viewers also tune in for the world famous commercials that send Facebook and Twitter abuzz. Daniela Schrier reports on the social media rewards for America’s priciest advertising.
Video

Video Theologians Cast Doubt on Morality of Drone Strikes

In 2006, stirred by photos of U.S. soldiers mistreating Iraqi prisoners, a group of American faith leaders and academics launched the National Religious Campaign Against Torture. It played an important role in getting Congress to investigate, and the president to ban, torture. VOA's Jerome Socolovsky reports.
Video

Video Freedom on Decline Worldwide, Report Says

The state of global freedom declined for the ninth consecutive year in 2014, according to global watchdog Freedom House's annual report released Wednesday. VOA's William Gallo has more.
Video

Video As Ground Shifts, Obama Reviews Middle East Strategy

The death of Saudi Arabia’s king, the collapse of a U.S.-friendly government in Yemen and a problematic relationship with Israel’s leadership are presenting a new set of complications for the Obama administration and its Middle East policy. Not only is the U.S. leader dealing with adversaries in Iran, the Islamic State and al-Qaida, but he is now juggling trouble with traditional allies, as White House correspondent Luis Ramirez reports.
Video

Video MRI Seems to Help Diagnose Prostate Cancer, Preliminary Study Shows

Just as with mammography used to detect breast cancer, there's a lot of controversy about tests used to diagnose prostate cancer. Fortunately, a new study shows doctors may now have a more reliable way to diagnose prostate cancer for high risk patients. More from VOA's Carol Pearson.
Video

Video Smartphones About to Make Leap, Carry Basic Senses

Long-distance communication contains mostly sounds and pictures - for now. But scientists in Britain say they are close to creating additions for our smartphones that will make it possible to send taste, smell and even a basic touch. VOA’s George Putic reports.
Video

Video NASA Monitors Earth’s Vital Signs From Space

The U.S. space agency, NASA, is wrapping up its busiest 12-month period in more than a decade, with three missions launched in 2014 and two this month, one in early January and the fifth scheduled for January 29. As VOA’s Rosanne Skirble reports, the instruments being lifted into orbit are focused on Earth’s vital life support systems and how they are responding to a warmer planet.
Video

Video Saved By a Mistake - an Auschwitz Survivor's Story

Dagmar Lieblova was 14 when she arrived at Auschwitz in December 1943, along with her entire Czech Jewish family. All of them were to die there, but she was able to leave after several months due to a bureaucratic mix-up which saved her life. Now 85, with three children and six grandchildren, she says she has a feeling of victory. This report by Ahmad Wadiei and Farin Assemi, of RFE/RL's Radio Farda is narrated by RFE’s Raymond Furlong.

Circumventing Censorship

An Internet Primer for Healthy Web Habits

As surveillance and censoring technologies advance, so, too, do new tools for your computer or mobile device that help protect your privacy and break through Internet censorship.
More

All About America

AppleAndroid